MA42654A - Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt - Google Patents

Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt

Info

Publication number
MA42654A
MA42654A MA042654A MA42654A MA42654A MA 42654 A MA42654 A MA 42654A MA 042654 A MA042654 A MA 042654A MA 42654 A MA42654 A MA 42654A MA 42654 A MA42654 A MA 42654A
Authority
MA
Morocco
Prior art keywords
pyridin
acrylamide
nampt
pak
modulators
Prior art date
Application number
MA042654A
Other languages
English (en)
Inventor
Erkan Baloglu
William Senapedis
Sharon Shacham
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MA42654A publication Critical patent/MA42654A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA042654A 2015-08-17 2016-08-17 Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt MA42654A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562205964P 2015-08-17 2015-08-17

Publications (1)

Publication Number Publication Date
MA42654A true MA42654A (fr) 2018-06-27

Family

ID=56799625

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042654A MA42654A (fr) 2015-08-17 2016-08-17 Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt

Country Status (4)

Country Link
US (1) US20190218207A1 (fr)
EP (1) EP3337796A1 (fr)
MA (1) MA42654A (fr)
WO (1) WO2017031213A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440515B (zh) 2013-07-03 2022-05-03 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
WO2015042414A1 (fr) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Composés multicycliques et leurs procédés d'utilisation
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Composés multicycliques et leurs utilisations
ES2957464T3 (es) * 2017-04-14 2024-01-19 Univ Arizona Composiciones y métodos para tratar fibrosis pulmonar
WO2018191747A1 (fr) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et procédés pour le traitement de l'hypertension pulmonaire
WO2019036024A1 (fr) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company Dérivés de 2-(1,1'-biphényl)-1h-benzo[d]imidazole et composés apparentés en tant qu'agonistes d'apéline et d'apj pour le traitement de maladies cardiovasculaires
CN111205232B (zh) * 2020-02-26 2022-07-01 浙江天宇药业股份有限公司 一种替格瑞洛中间体的合成方法
CN117624088A (zh) * 2023-12-06 2024-03-01 中科国生(杭州)科技有限公司 一种氢化制备2,5-呋喃二甲胺的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440515B (zh) * 2013-07-03 2022-05-03 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
WO2015042414A1 (fr) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Composés multicycliques et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3337796A1 (fr) 2018-06-27
US20190218207A1 (en) 2019-07-18
WO2017031213A1 (fr) 2017-02-23

Similar Documents

Publication Publication Date Title
IL283582A (en) Modulators of ror-gamma
EP3490565A4 (fr) Modulateurs de récepteurs de chimiokine et leurs utilisations
MA50014A (fr) Modulateurs de k-ras
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
EP3353328A4 (fr) Modulateurs de l'expression de kras
MA43382A (fr) Modulateurs des récepteurs des chimiokines
MA44075A (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EP3356381A4 (fr) Dérivés nucléotidiques et leurs méthodes d'utilisation
MA55328A (fr) Modulateurs de ror-gamma
DK3331876T3 (da) Modulators of ror-gamma
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
PT3160964T (pt) Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
FR3021533B1 (fr) Composition cosmetique de type gel
EP3450460A4 (fr) Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation
LT3294713T (lt) Pakeisti tetrahidrokvinoliniai junginiai, kaip ror gama moduliatoriai
LT3319963T (lt) Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
EP3580223A4 (fr) Modulateurs du récepteur des strogènes de benzothiophène
MA40759A (fr) Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
LT3685847T (lt) Komplemento aktyvumo moduliatoriai
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
EP3353303A4 (fr) Compositions et méthodes de modulation de l'expression de l'ataxine 3
HUE056613T2 (hu) Komplementaktivitás modulátorai
EP3532062A4 (fr) Modulateurs de ror-gamma
EP3356530A4 (fr) Modulateurs tlr et méthodes d'utilisation associées
EP3734470A4 (fr) Système de proposition de destination, dispositif de proposition et procédé de proposition